Kidney Week 2025 Early Program - Diabetes Management for the Nephrology Care Team: New Technology and New Drugs
Availability
On-Demand
Cost
Member: $400.00
Non-Member: $700.00
Contains (14)
Welcome and Introduction
Not Always Typical: Update on Diabetes Classification
The Good, the Bad, and the Ugly: Biomarkers to Assess Average Blood Glucose
The Cutting Edge of Current CGM Technology
CGM Sensor Application
Interpreting the Ambulatory Glucose Profile
Pushing Back the Curtain: CGM in Patients on Dialysis
Panel Discussion: Case Studies in CGM Interpretation
Use of Glucose-Lowering Therapies in CKD
How to Use Incretin Mimetics in Nephrology Clinic
Use of GLP-1 Receptor Agonists in Patients on Dialysis and in Kidney Transplant Recipients
Pumps, Pens, and New Insulins
Combination Therapies for Holistic Health in T2D and Kidney Disease
Panel Discussion: Case Studies in Diabetes Management

This program brings together members of the nephrology care team to discuss the cutting edge of rapidly advancing diabetes technologies and treatments. Diabetes is the most common cause of CKD and kidney failure requiring dialysis or kidney transplantation. Continuous glucose monitoring (CGM), insulin pumps, and closed-loop technology (automated insulin delivery [AID]) have revolutionized diabetes care. New drug classes are also available to treat diabetes and reduce CKD-related complications, including progression to kidney failure and cardiovascular disease.

Nephrology care teams are well positioned to help implement new diabetes treatments according to current guidelines. Nephrology care teams often assume comprehensive care for patients with complex disease, including those with advanced CKD, kidney failure, and kidney transplants. Since many of these patients have diabetes, optimal diabetes management is an important part of their care. Given the presentation of type 1 diabetes in adults and type 2 diabetes in the pediatric population and the discovery of atypical forms of diabetes, correct diabetes classification is imperative because the treatment strategies differ depending on the etiology.

Learning Objectives
Upon completion of the program, the participant will be able to:

  • Describe diabetes diagnosis, classification, and assessment
  • Discuss current technology and interpretation of CGM
  • Explain how and for whom to prescribe new diabetes drugs
  • Describe how CGM and new treatments can be used for patients with diabetes and various stages of CKD

Target Audience

  • Physicians
  • Researchers
  • Medical and Other Trainees
  • Nurses and Nurse Practitioners
  • Pharmacists
  • Physician Assistants
  • Other Healthcare Professionals

Commercial Support
ASN thanks Abbott Diabetes Care Inc. and Dexcom for in-kind support (continuous glucose monitoring sensors).

Privacy Policy/Confidentiality

http://www.asn-online.org/terms/privacy.aspx    
    
ASN Medical Disclaimer     
http://www.asn-online.org/terms/medical-disclaimer.aspx

For a successful viewing experience, the following hardware and software are required:
  • Broadband cable, DSL, or high-speed internet connection
  • Please use the latest version of Google Chrome for the best viewing experience. Mozilla and Safari can also be used; however, Microsoft Edge is not recommended. Please check the ASN auto-detect settings page.
  • 533 MHz or faster processor
  • 512 MB RAM or higher
  • Adobe Reader (free download)
  • Computer which can play MP3 files
  • Apple iPad/iPhone running HTML5
  • Android devices  
Note: If you are experiencing technical difficulties, please contact education@asn-online.org for assistance.